Whole genome association studies of neuropsychiatric disease: An emerging era of collaborative genetic discovery

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 5, 2007, Pages 613-618

  Keller, Margaret A ^a   Gwinn, Katrina ^b   Nash, Josefina ^a   Horsford, Jonathan ^c   Zhang, Ran ^b   Rich, Stephen S ^d   Corriveau, Roderick A ^a  

^a Laboratory of Molecular and Cellular Biology of Hematopoiesis   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bioinformatics; Consent; Genetics; Human; Neurology; Repository

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ATTENTION DEFICIT DISORDER; BIOINFORMATICS; BIPOLAR DISORDER; CONFIDENTIALITY; DATA COLLECTION METHOD; FAMILY HISTORY; GENE SEGREGATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HERITABILITY; HUMAN; INFORMATION DISSEMINATION; INFORMATION PROCESSING; INFORMED CONSENT; INHERITANCE; INSULIN DEPENDENT DIABETES MELLITUS; LINKAGE ANALYSIS; MAJOR DEPRESSION; MENTAL DISEASE; MUTATIONAL ANALYSIS; PHENOTYPIC VARIATION; POPULATION GENETICS; PRIVACY; PSORIASIS; REVIEW; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 36048945679     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Bonifati V, Rohe CF, Breedveld GJ, et al. 2005. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology, 65:87-95.
2. Eriksen JL, Przedborski S, Petrucelli L. 2005. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med, 11:91-6.
3. Fiegler H, Redon R, Andrews D, et al. 2006. Accurate and reliable high-throughput detection of copy number variation in the human genome. Genome Res, 16:1566-74.
4. Fung HC, Scholz S, Matarin M, et al. 2006. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol, 5:911-16.
5. Gwinn-Hardy K. 2002. Genetics of parkinsonism. Mov Disord, 17:645-56.
6. Kaluzny AD, Lacey LM, Warnecke R, et al. 1993. Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program. Health Serv Res, 28:159-82.
7. Kapetanaki MG, Guerrero-Santoro J, Bisi DC, et al. 2006. The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. Proc Natl Acad Sci USA, 103:2588-93.
8. Khaja R, Zhang J, Macdonald JR, et al. 2006. Genorne assembly comparison identifies structural variants in the human genorne. Nat Genet, 38:1413-18.
9. Martins CA, Oulhaj A, de Jager, et al. 2005. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology, 65:1888-93.
10. Matsuura S, Matsumoto Y, Morishima K, et al. 2006. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. Am J Med Genet A, 140:358-67.
11. Mitelman F, ed. 1998. Catalog of Chromosome Aberrations in Cancer '98.
12. Mizuno Y, Hattori N, Yoshino H, et al. 2006. Progress in familial Parkinson's disease. J Neural Transm Suppl, 191-204.
13. Namboodiri KK. 1984. Framingham Heart Study: review of genetic data and design, limitations and prospects. Prog Clin Biol Res, 147:65-78.
14. Nishioka K, Hayashi S, Farrer MJ, et al. 2006. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol, 59:298-309.
15. Ouahchi K, Lindeman N, Lee C. 2006. Copy number variants and pharmacogenomics. Pharmacogenomics, 7:25-9.
16. Ragoussis J, Elvidge GP, Kaur K, et al. 2006. Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research. PLoS Genet, 2:e100.
17. Redon R, Ishikawa S, Fitch KR, et al. 2006. Global variation in copy number in the human genome. Nature, 444:444-54.
18. Rivolta C, McGee TL, Rio Frio T, et al. 2006. Variation in retinitis pigmentosa-11 (PRPF31 or RP11) gene expression between symptomatic and asymptomatic patients with dominant RP11 mutations. Hum Mutat, 27:644-53.
19. Simon-Sanchez J, Hanson M, Singleton A, et al. 2005. Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. Neurosci Lett, 382:191-4.
20. Simon-Sanchez J, Scholz S, Fung HC, et al. 2006. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet.
21. Stefansson H, Sigurdsson, Steinthorsdottir V, et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet, 71:877-92.
22. Tchinda J, Lee C. 2006. Detecting copy number variation in the human genome using comparative genomic hybridization. Biotechniques, 41:385, 387, 389 passim.
23. Wang WY, Barratt BJ, Clayton DG, et al. 2005. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet, 6:109-18.
24. White SJ, den Dunnen JT. 2006. Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res, 115:240-6.
25. Wood-Kaczrnar A, Gandhi S, Wood NW. 2006. Understanding the molecular causes of Parkinson's disease. Trends Mol Med, 12:521-8.
26. Yata J, Desgranges C, Nakagawa T, et al. 1975. Lymphoblastoid transformation and kinetics of appearance of viral nuclear antigen (EBNA) in cord-blood lymphocytes infected by Epstein-Barr Virus (EBV). Int J Cancer, 15:377-84.
27. Yeager M, Orr N, Hayes RB, et al. 2007. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet.